Apitegromab is an investigational treatment aimed at improving motor function for people living with spinal muscular atrophy. Scholar Rock said it has also submitted and received validation for its ...

Since 2016, the FDA has approved three disease-modifying treatments for spinal muscular atrophy, with several ...

A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.

22. Apitegromab is an investigational treatment aimed at improving motor function for people living with spinal muscular atrophy. Scholar Rock said it has also submitted and received validation ...

A rare genetic condition, Spinal Muscular Atrophy (SMA) affects one in 7,000 people in India. It mostly affects children and ...

Apitegromab, a fully human monoclonal antibody, works by selectively binding to the pro- and latent forms of myostatin in order to inhibit myostatin activation.

Innovator drug price is Rs 22-72 lakh per year; Analysts forecast Natco to price generic drug at Rs 3,000 per year ...

Scholar Rock (SRRK) announced that the U.S. Food and Drug Administration FDA has accepted its Biologics License Application BLA for ...

Biogen enhances its portfolio and margins amidst market challenges and competition. Click here to find out why BIIB stock is ...

For patients who feel their Botox wears off quickly, Dr. Zalka often suggests increasing the dosage slightly. “Injecting a ...

Ligan 4033 stands as a lawful and secure substitute for Ligandrol 4033. This muscle-building supplement was originally ...